Viking Therapeutics (VKTX) trades on a $92 consensus price target from Wall Street—a 162 percent bet that its lead candidate VK2735 will capture meaningful share in obesity and type 2 diabetes treatment.
The bull case rests on two specific claims: VK2735, a dual GLP-1 and GIP agonist, delivers faster weight loss than existing therapies, and its dual-formulation design (injectable followed by oral maintenance) offers practical advantages over competitors' single modalities.
Key catalysts are concrete: phase 3 results for the subcutaneous formulation in H2 2027, phase 3 launch for the oral form later this year with readouts in 2028-2029, and imminent phase 1 maintenance trial data involving 180 patients.
The risk is equally specific. Eli Lilly's Zepbound (tirzepatide) already owns the market as the first-to-market dual agonist, backed by blockbuster sales and label expansion. Lilly is also advancing Foundayo (orforglipron), an oral option in the same class. Novo Nordisk's Wegovy and Rybelsus dominate injectable and oral diabetes segments, with additional oral obesity candidates in development. Amgen entered the category in 2024 with MariTide, a longer-acting GLP-1.
By the time Viking reads phase 3 data, the competitive set will be entrenched. The real bottleneck: clinical execution. VK2735's oral formulation faces specific safety and tolerability questions that competitors have already navigated. Trial failure—whether from efficacy miss or unacceptable side effects—would likely trigger a sharp stock decline.
For portfolio managers sizing biotech exposure here, the $92 target requires conviction that VK2735 outperforms in head-to-head comparisons and that first-mover disadvantage can be overcome with a materially better drug. Neither is guaranteed.
